Chronic liver diseases leading to cirrhosis and hepatocellular carcinoma are a major cause of morbidity and mortality worldwide. 1 The burden of illness due to chronic liver diseases is linked to three major etiologies: viral hepatitis (B, C, and D), alcoholic liver disease, and nonalcoholic fatty liver disease (NAFLD). 1, 2 With the widespread use of vaccination for hepatitis B and the advent of more potent directly acting antiviral therapies against hepatitis C, the prevalence of end-stage liver disease (ESLD) due to viral hepatitis is expected to decline in the coming decades.
1,3,4
Although there have been dramatic advances in antiviral therapies, treatment options remain limited for both alcoholic liver disease and NAFLD. In contrast, due to the rising rates of obesity and metabolic syndrome that are commonly associated risk factors for NAFLD, it is expected to be the leading cause of cirrhosis and ESLD in the coming decades, especially in the developed world. 5, 6 Over the past several years, significant interactions between the intestinal microbiota and liver have been discovered with possible mechanisms for the development as well as progression of liver disease; these discoveries have provided invaluable insight into promising therapeutic targets to either prevent or halt the progression of liver disease. Our understanding of human gut microbiome is still in its infancy, especially as it relates to liver disease. Greater than 10 14 microorganisms live in the human gastroenterological tract, including bacteria, viruses, fungi, and archaea; this collective microbial community is known as the gut microbiome. Most of the bacteria are anaerobic, with varying numbers and composition according to the site in the gut, increasing from the stomach to the small intestine to the colon. Over 90% of the intestinal bacteria belong to the phyla Firmicutes and Bacteroidetes. 7 Although these main phyla are consistently seen, the species present and their relative proportions vary considerably between individuals. 8 Due to the presence of a large number of anaerobic, fastidious organisms, the analysis of gut microbiota has evolved beyond culture-based techniques to enable sequencing of whole genomes.
9
The gut microbiota is beneficial for host metabolism, aids in digestion, and contributes to normal immune function, thereby creating a symbiotic relationship with the host.
Intestinal dysbiosis is defined as a disruption in symbiosis due to an imbalance in the microbial composition. This can present as quantitative (intestinal bacterial overgrowth) and/or qualitative changes in the intestinal microbiota.
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The gut microbiota plays a critical role in the gut and systemic immune system and has been potentially implicated in several different diseases, including obesity, neurologic diseases, inflammatory bowel disease, cancer, and liver disease. 8 Our aim here is to examine mechanisms of dysbiosisinduced liver disease; highlight current knowledge regarding the role of dysbiosis in NAFLD, alcoholic liver disease, and cirrhosis; and review potential therapeutic targets.
Mechanisms of Liver Disease in Dysbiosis
The liver is particularly susceptible to potential effects of dysbiosis. Greater than 70% of the liver's blood supply is via the portal vein, resulting in frequent exposure of gut-derived toxins and microbial products. In normal conditions, small amounts of bacteria and bacterial metabolites enter the liver and are rapidly cleared. However, when the normal gut barrier is disrupted such as in intestinal dysbiosis, large amounts of bacteria and bacterial products enter the liver resulting in the activation of the immune cascade, production of proinflammatory cytokines, and subsequent liver damage.
11 Mechanisms of dysbiosis-induced liver disease include increased intestinal permeability, bacterial/metabolite translocation, and immune activation (►Fig. 1). Increased intestinal permeability is attributed to tight junction disruption, possibly from metabolites or dysbiosis-induced inflammation. [12] [13] [14] [15] Augmented gut permeability results in increased translocation of bacteria, bacterial products (such as lipopolysaccharide/endotoxin), and metabolites into the portal circulation. Metabolites such as trimethylamine (produced from bacterial enzymatic cleavage of dietary choline) and alcohol (produced by enteric bacteria) can have direct toxic effects on the liver, whereas bacterial products cause liver damage through activation of the innate immune system.
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Foreign pathogens (such as bacteria, viruses, and fungi) are recognized by pathogen recognition receptors, such as tolllike receptors (TLRs) and inflammasomes. TLRs are expressed on cells in the hepatic sinusoids (including Kupffer cells and Fig. 1 Mechanisms of liver disease in dysbiosis. Under normal conditions, gut integrity is preserved with minimal entry of bacterial products into the portal circulation. In the liver, hepatocytes and Kupffer cells rapidly clear microbial products and maintain immunotolerance without inflammation. In dysbiosis, intestinal permeability is increased, resulting in increased translocation of bacteria, metabolites, and microbial products. Metabolites have direct toxic effects on the liver. Activation of the innate immune system via toll-like receptors and inflammasomes by bacteria and bacterial products produces large amounts of inflammatory cytokines and subsequent liver damage. 
Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease is defined as hepatic steatosis on either liver histology or imaging without any secondary causes of hepatic fat accumulation such as alcohol consumption. 23 Nonalcoholic fatty liver disease can be broadly classified into two categories: nonalcoholic fatty liver (NAFL), which is considered to have minimal risk of liver disease progression; and nonalcoholic steatohepatitis (NASH), which is considered to have a substantially higher risk of liver disease progression. 24 Nonalcoholic steatohepatitis is defined as the presence of hepatic steatosis typically in zone 3 with lobular inflammation and ballooning with or without perisinusoidal fibrosis. 23 Obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome are all risk factors for NAFLD.
23,25
Although there are many animal and human studies demonstrating the effects of gut microbiota on energy absorption, obesity, and insulin resistance, in this review we will focus primarily on selected studies describing the association of dysbiosis with NAFLD.
26,27
Recent studies have suggested that fibrosis progression is substantially higher in NASH versus NAFL; it is likely that the various stages of liver diseases may have the following steps: normal to NAFL to borderline NASH to definite NASH to cirrhosis. 24 and changes in bile acid metabolism.
38
Additional animal studies have improved our understanding of the role of gut microbiota in development of NAFLD and its contributions toward the progression from NAFL to NASH. These studies have suggested multiple mechanisms for liver injury in steatohepatitis. One mechanism is that endotoxin production from gut microbiota results in the activation of Kupffer cells via the TLR-4 complex and subsequent release of inflammatory mediators that promote steatohepatitis.
21
TLR-4-deficient mice and Kupffer cell-depleted mice have decreased steatohepatitis compared with wild-type mice. In addition, inflammasome plays an important role in preventing the progression of NAFL to NASH. Inflammasomedepleted mice develop dysbiosis that results in more severe steatohepatitis. This phenotype was mediated through an influx of TLR-4 and TLR-9 agonists into the portal vein, ultimately resulting in the activation of tumor necrosis factor α (TNF-α) in the liver.
39
Nevertheless, the physiological phenomena observed in animal studies have been difficult to demonstrate in humans. Most human studies investigating the role of intestinal microbiota in NAFLD/NASH have instead focused on the compositional differences between those who have the disease (or trait), and those who do not. Initial real-time polymerase chain reaction analysis of the fecal microbiome among patients with NAFL, NASH, and healthy controls demonstrated a lower percentage of Bacteroidetes among NASH patients, a finding that was independent of body mass index (BMI) and diet.
40 Subsequent studies, using 16S rRNA sequencing of the fecal microbiome, showed a more nuanced picture of the gut microbiome, with overrepresentation of several Firmicutes genera such as those belonging to Lactobacillus, Dorea, Robinsoniella, and Roseburia, but underrepresentation of other Firmicutes genera such as Oscillibacter. 41, 42 Similar findings are reported in a pediatric population. 35 ►Table 1 reviews changes in intestinal microbiota composition among human studies of NAFLD. However, these studies did not control for various factors that are now known to have an effect on the composition of the gut microbiome in humans, such as diet in the days immediate to fecal sample collection. 43 Furthermore, there is ongoing debate as to whether bacteria residing in the mucous layer, where it more intimately interacts with the host cells, are more likely to affect host physiology than luminal bacteria, found in fecal samples. It should also be noted that Lactobacillus genera contains multiple members that are particularly adapted to be commensal gut species.
Other studies have found that particular lactobacillus species can be protective against hepatic injury, 44 hence the diversity of this genera, with both protective and disruptive member species, should be fully appreciated. Nevertheless, there have been observations in humans that indicate that the compositional differences observed in humans can play a role in the pathophysiology of NAFLD/ Targeting Dysbiosis for the Treatment of Liver Disease Anand et al. 39
NASH. For example, shifts in the fecal microbiome composition correlated with an increase in fecal ester volatile organic compounds among obese patients with NAFLD compared with healthy lean control patients. 41 Volatile organic compounds are metabolic products that may have direct toxic effects on the liver via the portal circulation. In addition, there is an increase in small intestinal permeability and small intestinal bacterial overgrowth (SIBO) among patients with NAFLD compared with controls, which may influence the development of hepatic steatosis.
12

Gut Microbiome and Bile Acid Signaling
The observed compositional changes in humans have also been reported in animal models of NAFLD. Mice with obesity, dysmetabolism, and hepatic steatosis also have a rise in Lactobacillus species and a decrease in Oscillibacter species. 45, 46 These compositional changes in the gut microbiome have been linked to altered luminal secondary bile acid profiles, specifically by an increase in bile acid hydrolases in Lactobacillus species. 47, 48 The modulation of the luminal bile acid profiles, in turn affect bile acid signaling by the farnesoid X receptor 49 and the G protein-coupled bile acid receptor 1. 50 Interestingly, agents that modulate bile acid signaling, such as obeticholic acid, are being vigorously investigated as novel treatments for NAFLD/NASH.
51,52
Future NAFLD/NASH therapies that target the microbiome will likely mediate their affects by a combination of modulating host metabolism by bile acid signaling and host inflammation through TLR-4/inflammasome pathways. In summary, animal and human studies have demonstrated differences in gut microbiota with NAFLD. Furthermore, there is emerging evidence to suggest that the gut microbiota may play a key role in the development of hepatic steatosis and progression from NAFL to NASH. However, whether the gut microbial dysbiosis is causally related to liver disease progression in patients with NASH cirrhosis remains to be elucidated.
Alcoholic Liver Disease
Alcoholic liver disease encompasses a spectrum of disease including hepatic steatosis, acute alcoholic hepatitis, chronic hepatitis with fibrosis, and cirrhosis. Development and progression of alcoholic liver disease is influenced by several factors including quantity of alcohol, consumption pattern, presence of obesity, gender, nutritional status, genetic polymorphisms, and the presence of chronic viral hepatitis. 53 Recently, data have emerged demonstrating an important role of intestinal microbiota in the development of alcoholic liver disease. Alcohol use has both quantitative as well as qualitative effects on the gut microbiota. Alcohol use leads to decreased intestinal motility that can lead to the proliferation of intestinal bacteria. 54 Several mouse and human studies have also demonstrated alterations in the composition of the intestinal microbiota with alcohol consumption. Chronic alcohol exposure in mice leads to significant changes in the intestinal microbiota. 55 Chronic alcohol feeding resulted in a decline in Bacteroidetes and Firmicutes with an increase in Proteobacteria and Actinobacteria. Furthermore, the alcohol-fed mice had increased plasma endotoxin levels, higher fecal pH, and greater liver inflammation. Similar findings were observed in patients with chronic alcohol use. These patients had a lower quantity of Bacteroidetes and higher quantity of Proteobacteria when compared with control participants.
56
In addition to alterations in intestinal microbiota, alcohol use has other effects on the gastrointestinal tract, which may contribute to liver toxicity such as increasing intestinal permeability.
13 Acetaldehyde, a metabolic product of alcohol, induces increased gut permeability through the disruption of epithelial tight junctions and adherens junctions. [57] [58] [59] [60] Increased gut permeability has also been attributed to increased intestinal inflammation through the production of TNF-α in the lamina propria, which results in disruption of tight junctions.
61,62
Overall, chronic alcohol use results in changes in the composition of intestinal microbiota and induces bacterial overgrowth. Furthermore, intestinal dysbiosis and metabolic products of alcohol promote gut hyperpermeability. As a result, bacteria and microbial products such as gut-derived lipopolysaccharides (endotoxin) can translocate into the portal circulation. Compared with control participants, patients with chronic alcohol use have an increase in plasma endotoxin levels in all stages of alcoholic liver disease. Furthermore, alcoholic cirrhotics also have higher levels of endotoxin when compared with patients who have cirrhosis from other causes. 
70-72
In addition to the proliferation of bacteria and compositional change of microbiota to potentially more pathogenic strains of bacteria, there is increased bacterial translocation with cirrhosis that may have clinical consequences. 15 This was illustrated by comparing the bacterial cultures in mesenteric lymph nodes from noncirrhotics and cirrhotics, stratified by Childs-Pugh class. 73 Enteric organisms grew from mesenteric lymph nodes in 30.8% of Childs C cirrhotics compared with 8.6% of noncirrhotics. Results were similar among noncirrhotics, Childs A cirrhotics and Childs B cirrhotics. Culture-based studies may underestimate true bacterial translocation due to the presence of fastidious anaerobic organisms, which are difficult to grow in a laboratory setting. Thus, more recent studies have measured bacterial DNA as an indicator of bacterial translocation. About 32% of patients with cirrhosis have detectable bacterial DNA in their blood and ascitic fluid, whereas no bacterial DNA was detected in the blood of healthy controls. 74 Interestingly, all patients had nonneutrocytic sterile ascites and negative blood cultures. Factors promoting bacterial translocation in cirrhosis include increased intestinal permeability, SIBO, and host immunological alterations.
15
Potential clinical consequences of dysbiosis and increased bacterial translocation in cirrhosis are worsened hyperdynamic circulation, infection, and hepatic encephalopathy.
75
Patients with bacterial DNA in their ascites had significantly lower mean arterial pressure, lower systemic vascular resistance, and signs of worsened hepatic endothelial function compared with patients without ascitic fluid bacterial DNA.
In terms of infection, it remains unclear if dysbiosis is a risk factor for the development of infections. However, patients with cirrhosis have an increased presence of potentially pathogenic species that are commonly involved in systemic infections with a decrease in commensal bacteria, raising the Targeting Dysbiosis for the Treatment of Liver Disease Anand et al. 41
concern for an interaction of dysbiosis and infection. A comparison of 38 infected cirrhotic patients to uninfected cirrhotic patients found increased dysbiosis (reflected by lower CDR) and higher serum endotoxin levels among infected patients. 63 
Targeting Dysbiosis
The gut microbiome can be modulated in different ways, and targeting intestinal dysbiosis has been investigated as a way to combat liver disease. Therapies include prebiotics, probiotics, synbiotics, antibiotics, and fecal microbiota transplantation (►Table 2). 76 Prebiotics are nondigestible carbohydrates that promote beneficial changes in the activity and composition of gastrointestinal microflora. Probiotics are living microorganisms (bacteria, fungi) that present a health benefit for the host. Synbiotics contain both prebiotics and probiotics.
76,77
Prebiotics
Prebiotics are complex carbohydrates including lactulose, inulin, fructo-oligosaccharides (FOS), and galacto-oligosaccharides (GOS), which stimulate the growth of certain bacteria, most commonly Bifidobacteria and Lactobacilli. 78 There are limited data describing the effects of other prebiotics in liver disease. Although prebiotics are nondigestible by the host, they are fermented by colonic microbes to form shortchain fatty acids (SCFAs) and lactate. 79 The production of SCFAs has been shown to modulate cytokine production and may have immunomodulatory effects. Lactulose is probably the best-studied prebiotic in liver disease and is commonly used for the treatment of hepatic encephalopathy. However, studies have shown different compositional outcomes in patients with cirrhosis who are taking lactulose. In one study, lactulose administration resulted in decreased stool pH and increased Lactobacilli in the stool. 80 In another study, however, there was greater dysbiosis, reflected by a decline in CDR, without a change in Lactobacilli. 63 In the latter study, only seven patients were included and these results may be limited by a small sample size. In patients with alcoholic liver disease, there is strong evidence in animal models that prebiotics could play a protective role. 81 Chronic alcohol consumption affects bacterial synthesis of saturated long-chain fatty acids (LCFAs). When LCFAs were added to the diet in mice models of alcoholic liver disease, there was an improvement in the function of the epithelial barrier and reduction in liver injury. Furthermore, changes were also noted in the composition of the gut microbiome with an increase in Lactobacilli species. Therefore, prebiotics that may augment LCFA production may be helpful in the treatment of alcoholic liver disease. Randomized, controlled clinical trials along with mechanistic studies are needed to better assess the role of prebiotics in improving alcoholic hepatitis and alcoholic cirrhosis.
Probiotics
Probiotics are living microorganisms that confer a health benefit on their host through antimicrobial effects, enhancement of mucosal barrier integrity, and immunomodulation. 76 Antimicrobial effects of probiotics are related to the production of antimicrobial products (such as bacteriocins and hydrogen peroxide), competitive colonization with other microbes, and production of organic acids that acidify the lumen, inhibiting growth and colonization of pathogenic bacteria. 82 Enhancement of the mucosal barrier is accomplished through stimulation of mucin production and enhanced tight junction function through the actions of butyrate, a SCFA produced by probiotics. Targeting Dysbiosis for the Treatment of Liver Disease Anand et al.
These immunomodulating interactions result in changes in cytokine production that can inhibit epithelial cell apoptosis. 84 Commonly used and studied probiotics include Lactobacillus GG (LGG), Lactobacillus casei, Lactobacillus plantarum, Lactobacillus johnsonii, Bifidobacterium lactis, and Saccharomyces boulardii and VSL#3, which is a probiotic combination consisting of eight strains of Lactobacilli, Bifidobacteria, and Streptococcus.
Over the past few years, there have been an increasing number of studies evaluating the effect of probiotics in liver disease. Several small clinical trials have evaluated the effect of probiotics (predominantly Lactobacillus, VSL#3, Bifidobacterium) in patients with NAFLD with varying results. [85] [86] [87] [88] [89] The main outcomes in these studies were improvement in liver enzymes (serum alanine [ALT] and aspartate [AST] aminotransferases), inflammatory markers, and anthropometric measurements. Two studies measured changes in steatosis via magnetic resonance spectroscopy but none of the studies assessed liver histological response to probiotics. 87, 89 A metaanalysis found significantly improved levels of ALT, AST, TNF-α, and cholesterol with probiotic use among patients with NAFLD but included two studies which used synbiotics.
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Overall, clinical data remain limited to recommend the use of probiotics as therapy for patients with NAFLD and larger randomized controlled trials with either resolution of NASH or improvement in hepatic fibrosis on histology as endpoint are needed In alcoholic liver disease, animal studies have shown probiotics can reduce endotoxinemia and liver injury associated with alcohol consumption. A recent study has evaluated liver histology and serum endotoxin levels in rats fed alcohol compared with rats fed alcohol and LGG. The group treated with LGG had minimal histological liver damage and significantly lower serum endotoxin levels. 91 In addition, LGG was associated with less liver injury and diminished gut leakiness in a steatohepatitis rat model. 92 Administration of oats as a prebiotic or LGG as a probiotic prevented alcohol-induced dysbiosis in rats. 93 There are a limited number of human studies evaluating the effects of probiotics on alcoholic liver disease. The theoretical benefit of probiotics in hepatic encephalopathy is from decreasing nonurease-producing bacteria, resulting in decreased ammonia production. There are now multiple randomized control trials evaluating the role of probiotics in overt and minimal hepatic encephalopathy. In 2011, a Cochrane Review evaluated seven clinical trials and found that probiotics reduce plasma ammonia levels, but concluded there is insufficient evidence to support efficacy in treating hepatic encephalopathy. 100 The study highlighted methodological issues with concerns for bias and random error. In the past few years, additional clinical trials have been published. An open-label randomized trial evaluating the use of VSL#3 for the primary prophylaxis of hepatic encephalopathy found decreased hepatic encephalopathy (9% vs. 20%) in the probiotic group compared with the control group. 101 In addition, a phase I randomized control trial evaluating the safety and tolerability of LGG among cirrhotic patients with minimal hepatic encephalopathy was recently performed. 102 The LGG was well tolerated and associated with a reduction in endotoxemia and dysbiosis, but no change in cognition. Most studies have revealed no severe adverse reactions to the use of probiotics. Although there are now multiple animal and human studies highlighting the promise of probiotics in liver disease, large well-designed randomized clinical trials with either reducing the risk of hospitalization or improving survival as an endpoint are needed to elucidate potential benefits of probiotics in patients with hepatic encephalopathy or decompensated cirrhosis. In addition to determining efficacy, there are major questions regarding the specific strains of effective probiotics, optimal dosing, duration of therapy, and longterm consequences of probiotic use.
Synbiotics
Synbiotics combine prebiotics and probiotics with the theoretical goal of augmenting the activity and prolonging the survival of potentially beneficial probiotics. There are limited clinical studies evaluating the use of synbiotics in liver disease. The effects of Protexin, a synbiotic capsule containing seven bacterial strains (mostly Lactobacilli, Streptococci, Bifidobacteria) and FOS, were recently investigated on patients with NAFLD (based on imaging and laboratory diagnosis). (based on transient elastography) compared with placebo despite similar changes in BMI and waist-to-hip ratio in both groups. The effects of Bifidobacterium longum and FOS have also been evaluated on patients with biopsy-proven NASH. Patients treated with synbiotics had statistically significant declines in AST, inflammatory markers, serum endotoxin levels, and histological NASH activity score compared with a placebo despite similar declines in BMI in both groups.
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However, ALT was similar between the two groups at the end of the study.
Synbiotics have also been assessed in hepatic encephalopathy. The effects of Bifidobacterium and FOS have been compared with lactulose in a cohort of patients with mildto-moderate hepatic encephalopathy. 105 Patients in the synbiotic group had statistically significant declines in ammonia levels and improvements in psychometric testing compared with the lactulose-treated group. In addition, the effects of a synbiotic preparation, consisting of fermentable fiber (inulin, pectin, β glucan, and resistant starch) and four strains of bacteria (Pediacoccus pentoseceus, Leuconostoc mesenteroides, Lactobacillus paracasei, and Lactobacillus plantarum) have been evaluated on patients with minimal hepatic encephalopathy. 106 Patients receiving synbiotics had statistically significant improvements in ammonia levels and reduction in endotoxin levels compared with placebo. Furthermore, 50% of patients in the synbiotic group experienced resolution of minimal hepatic encephalopathy based on psychometric tests compared with only 10% in the control group. Although these studies are promising, large well-designed clinical trials are needed to elucidate the efficacy of synbiotic use for patients with liver disease.
Antibiotics
Antibiotics have profound quantitative and qualitative effects on the intestinal microbiota, greatly affecting microbial biodiversity. 107, 108 The class of antibiotic and mechanism of action greatly influence the ultimate effect on gut microbiota. 107 In addition to changes in bacterial populations and composition, antibiotics also have significant effects on bacterial metabolic function and virulence. 107, 109 Patients with cirrhosis benefit from antibiotics in several settings such as prophylaxis for spontaneous bacterial peritonitis in high-risk patients, but it is unclear if these benefits are via modulation of gut microbiota. 110 Rifaximin is a minimally absorbable oral antibiotic commonly used in the treatment of hepatic encephalopathy. 111 An analysis of the effects of rifaximin on intestinal microbiota among patients with minimal hepatic encephalopathy found only minimal changes in microbial composition, but significant changes in microbial metabolic function. 109 These findings suggest that rifaximin's primary mechanism of action is altering metabolic function in the microbiota as opposed to promoting beneficial bacteria while decreasing harmful bacteria. Further studies are needed to elucidate the mechanisms by which antibiotics modulate gut microbiota and influence long-term outcomes in chronic liver diseases and decompensated cirrhosis.
Fecal Microbiota Transplant
Fecal microbiota transplant (FMT) has gained widespread acceptance as a highly effective therapy for the treatment of recurrent Clostridium difficile infection. 112 A major mechanism by which FMT influences the microbiota is through limiting the colonization of pathogens, a concept known as colonization resistance. Studies have also shown FMT may also influence microbial metabolic function in addition to microbiota composition. 113 Fecal microbiota transplant has not been evaluated in clinical liver disease, but a recent mouse study demonstrated proof of concept by successfully transplanting a consortium of eight bacteria with minimal urease gene content to create an enduring new bacterial community that exhibited reduction in fecal urease activity.
114
Conclusion
Preclinical and clinical studies show the emerging role of the gut microbiome in the development and progression of chronic liver diseases, particularly in NAFLD, alcoholic liver disease, and cirrhosis. Further research is needed to more clearly elucidate gut-liver homeostasis and mechanisms for dysbiosis induced liver injury in humans. Promising new therapies have emerged by which to modulate gut microbiota and potentially treat liver disease. However, current evidence is inadequate to recommend the use of probiotics, prebiotics, or synbiotics in liver disease. High-quality, well-designed, large, multicenter clinical trials are needed to determine the efficacy, optimal dosing, and duration of therapy of therapeutic agents that specifically modulate dysbiosis, and examine the influence of specific changes in gut microbiota on long-term clinical outcomes. 
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